Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CLNN

Clene Inc

May 26 • 09:33AM ET

6.73

+0.03 0.45 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: ANVS BIVI MNOV DMAC ALZN

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.21	Insider Own	22.13%	Shs Outstand	11.78M	Perf Week	-0.88%
Market Cap	85.99M	Forward P/E	-	EPS next Y	-1.34	Insider Trans	-24.92%	Shs Float	9.95M	Perf Month	13.87%
Enterprise Value	102.10M	PEG	-	EPS next Q	-0.33	Inst Own	13.91%	Short Float	8.79%	Perf Quarter	33.53%
Income	-33.51M	P/S	661.49	EPS this Y	36.10%	Inst Trans	5.98%	Short Ratio	1.82	Perf Half Y	-23.17%
Sales	0.13M	P/B	-	EPS next Y	20.67%	ROA	-142.67%	Short Interest	0.88M	Perf YTD	14.65%
Book/sh	-1.60	P/C	14.48	EPS next 5Y	-	ROE	-	52W High	13.50 -50.15%	Perf Year	183.97%
Cash/sh	0.46	P/FCF	-	EPS past 3/5Y	33.86% 34.50%	ROIC	-6093.27%	52W Low	2.28 195.16%	Perf 3Y	-64.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-24.94% -0.59%	Gross Margin	-996.27%	Volatility	7.60% 11.63%	Perf 5Y	-96.77%
Dividend TTM	-	EV/Sales	785.41	EPS Y/Y TTM	-11.47%	Oper. Margin	-15722.39%	ATR (14)	0.64	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.93	Sales Y/Y TTM	-61.71%	Profit Margin	-25009.70%	RSI (14)	51.87	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.94	EPS Q/Q	-716.57%	SMA20	0.11%	Beta	0.92	Target Price	30.67
Payout	-	Debt/Eq	-	Sales Q/Q	-81.48%	SMA50	8.12%	Rel Volume	0.24	Prev Close	6.70
Employees	79	LT Debt/Eq	-	Earnings	May 14 BMO	SMA200	4.17%	Avg Volume	481.25K	Price	6.73
IPO	Aug 27, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	-8.37% -70.47%	Trades		Volume	6,508	Change	0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy	$16
May-02-22	Initiated	Canaccord Genuity	Buy	$10
Sep-28-21	Initiated	Oppenheimer	Outperform	$20

May-14-26 08:00AM	Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights (GlobeNewswire) +8.46%
May-05-26 08:45AM	Clene Announces $7 Million Underwritten Offering of Common Stock (GlobeNewswire) -18.67%
08:00AM	Clene to Present at Upcoming May Conferences (GlobeNewswire)
May-04-26 08:00AM	After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS (GlobeNewswire) +31.76%
Mar-12-26 08:00AM	Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights (GlobeNewswire) +6.09%
12:07AM	Loading…
Feb-26-26 12:07AM	Clene Touts FDA Path for ALS Drug CNM-Au8, Highlights Biomarkers, Extends Cash Runway (MarketBeat) +8.06%
Feb-24-26 08:00AM	Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8 2026 Catalysts (GlobeNewswire) +9.80%
Feb-19-26 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jan-23-26 01:02AM	Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2 (MarketBeat)
Jan-16-26 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jan-12-26 08:30AM	Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting (GlobeNewswire) -19.00%
Jan-09-26 08:30AM	Clene Announces Registered Direct Offering of Over $28 Million (GlobeNewswire) +7.12%
Dec-09-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire) +6.31%
Dec-03-25 08:00AM	Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8 (GlobeNewswire) -22.03%
Dec-02-25 05:39PM	Clene to Provide CNM-Au8 ALS Program Update (GlobeNewswire)
08:00AM	Loading…
Nov-20-25 08:00AM	Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference (GlobeNewswire)
Nov-13-25 09:00AM	Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -22.42%
08:00AM	Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
Nov-10-25 05:15PM	Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -5.35%
Nov-06-25 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -14.19%
Oct-20-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Oct-15-25 08:30AM	Clene to Participate in a Panel Discussion at the Maxim Growth Summit (GlobeNewswire)
Sep-25-25 08:00AM	Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8 Improves Brain Energy Metabolism in Multiple Sclerosis Patients (GlobeNewswire)
Sep-04-25 08:30AM	Clene Presents Preclinical Data Supporting CNM-Au8 for the Treatment of Parkinson's Disease (GlobeNewswire) +6.44%
Sep-02-25 08:00AM	Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +20.11%
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
09:10AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:38AM	Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
Aug-13-25 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Aug-12-25 05:20PM	Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:30AM	Loading…
Aug-05-25 08:30AM	Clene to Present at the Canaccord 45th Annual Growth Conference (GlobeNewswire)
Aug-04-25 05:20PM	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates (Zacks) +7.16%
Jul-16-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream (GlobeNewswire)
Jun-30-25 08:00AM	Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings (GlobeNewswire)
Jun-09-25 09:00AM	Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025 (ACCESSWIRE)
May-20-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire)
May-07-25 09:15AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -10.53%
08:00AM	Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
08:00AM	Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
May-05-25 05:45PM	Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-16-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire)
Apr-15-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire)
Apr-14-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Apr-08-25 08:00AM	Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8 Treatment At the American Academy of Neurology Late-Breaking Science Session (GlobeNewswire) +7.52%
Apr-01-25 08:30AM	Clene to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire) -16.23%
Mar-25-25 08:30AM	Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 (NewMediaWire) -11.73%
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -5.31%
08:00AM	Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-12-25 08:00AM	Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment (GlobeNewswire)
Mar-06-25 08:30AM	Clene to Present at the 37TH Annual Roth Conference (GlobeNewswire)
Feb-27-25 09:15AM	Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 (ACCESSWIRE)
Feb-25-25 08:00AM	Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8 's Impact on NfL Reduction (GlobeNewswire)
Feb-14-25 11:29AM	Is Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In? (Insider Monkey) +5.48%
Jan-13-25 11:18AM	IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS (NewMediaWire)
Dec-30-24 09:20AM	IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) (NewMediaWire)
Dec-19-24 02:44PM	IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments (NewMediaWire)
08:00AM	Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan (GlobeNewswire)
Dec-11-24 11:15AM	IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway (NewMediaWire)
Dec-10-24 08:30AM	FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8 Biomarker Data in ALS (GlobeNewswire)
Nov-15-24 07:11AM	Clene price target lowered to $83 from $86 at Canaccord (TipRanks)
Nov-13-24 08:00AM	Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -9.06%
Oct-25-24 12:09PM	IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership (NewMediaWire)
Oct-21-24 01:13PM	IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences (NewMediaWire)
Oct-11-24 02:55PM	IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements (NewMediaWire)
Oct-09-24 01:31PM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences (NewMediaWire) +14.04%
08:00AM	Clene to Present at Upcoming October Conferences (GlobeNewswire)
Oct-03-24 10:46AM	IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M (NewMediaWire)
Oct-02-24 07:21AM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements (NewMediaWire) +6.30%
Oct-01-24 04:00PM	Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility (GlobeNewswire)
Sep-30-24 08:30AM	Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules (GlobeNewswire)
Sep-26-24 11:44AM	IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership (NewMediaWire)
Sep-16-24 08:30AM	Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data (GlobeNewswire) -17.06%
Sep-04-24 11:27AM	IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference (NewMediaWire) +12.50%
Sep-03-24 10:38AM	IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases (NewMediaWire) +12.33%
08:00AM	Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 12:13PM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast (NewMediaWire)
Aug-23-24 10:17AM	IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials (NewMediaWire)
Aug-13-24 12:47PM	IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions (NewMediaWire)
Aug-12-24 08:00AM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode (NewMediaWire)
Aug-09-24 09:00AM	IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates (NewMediaWire) +14.74%
Aug-08-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. (GlobeNewswire)
Aug-07-24 08:23AM	Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -23.47%
Aug-06-24 08:00AM	Clene Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS (GlobeNewswire) +47.00%
Aug-05-24 08:00AM	Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire) -7.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-12-24 10:34AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jul-11-24 09:00AM	Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS (GlobeNewswire) -9.61%
Jul-09-24 08:00AM	Clene Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -21.54%
Jun-24-24 08:00AM	Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-21-24 07:09AM	Clene Presents Preliminary Data for CNM-Au8 as a Potential Treatment for Rett Syndrome (GlobeNewswire)
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting (GlobeNewswire)
Jun-12-24 07:46AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-05-24 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
May-28-24 07:30AM	Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8 in ALS (ACT-EAP) (GlobeNewswire)
May-14-24 08:00AM	Clene to Present at Upcoming May Conferences (GlobeNewswire)

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

CEOMr. Robert Etherington MBA

M.B.A.Mr. Morgan R. Brown CPA

Chief Science OfficerMr. Mark G. Mortenson ESQ.

General Counsel & Corporate SecretaryMr. Jerry Miraglia J.D.

Head of Human ResourcesMs. Mary Anne Mcneil

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ugwumba Chidozie	10% Owner	May 12 '26	Sale	6.20	73,296	454,435	103,417	May 13 06:04 PM
Ugwumba Chidozie	10% Owner	May 11 '26	Sale	6.75	22,177	149,695	176,713	May 13 06:04 PM
Symbiosis II LLC	Former Board Member	May 11 '26	Proposed Sale	6.50	198,890	1,292,785		May 11 04:15 PM
Ugwumba Chidozie	10% Owner	May 04 '26	Sale	6.80	72,884	495,611	198,890	May 05 05:53 PM
Ugwumba Chidozie	10% Owner	May 01 '26	Sale	6.01	5,795	34,828	271,774	May 05 05:53 PM
Symbiosis II LLC	Former Board Member	May 04 '26	Proposed Sale	6.55	41,260	270,381		May 04 04:02 PM
Ugwumba Chidozie	10% Owner	Apr 29 '26	Sale	5.63	12,170	68,517	283,305	Apr 30 05:54 PM
Ugwumba Chidozie	10% Owner	Apr 30 '26	Sale	6.08	5,736	34,875	277,569	Apr 30 05:54 PM
Ugwumba Chidozie	10% Owner	Apr 28 '26	Sale	5.90	1,591	9,387	295,475	Apr 30 05:54 PM
Symbiosis II LLC	Former Board Member	Apr 28 '26	Proposed Sale	5.90	56,916	335,804		Apr 28 04:10 PM
Ugwumba Chidozie	10% Owner	Apr 21 '26	Sale	6.14	61,345	376,658	297,066	Apr 22 05:55 PM
Ugwumba Chidozie	10% Owner	Apr 20 '26	Sale	6.12	4,318	26,426	358,411	Apr 22 05:55 PM
Ugwumba Chidozie	10% Owner	Apr 17 '26	Sale	6.43	25,040	161,007	362,729	Apr 17 08:17 PM
Ugwumba Chidozie	10% Owner	Apr 16 '26	Sale	6.40	7,748	49,587	387,769	Apr 17 08:17 PM
Ugwumba Chidozie	10% Owner	Apr 15 '26	Sale	6.48	6,374	41,304	395,517	Apr 17 08:17 PM
Symbiosis II LLC	Former Board Member	Apr 15 '26	Proposed Sale	6.39	104,825	669,832		Apr 15 04:05 PM
Ugwumba Chidozie	10% Owner	Apr 02 '26	Sale	4.81	24,925	119,889	401,891	Apr 06 05:32 PM
Ugwumba Chidozie	10% Owner	Apr 01 '26	Sale	4.97	4,278	21,262	426,816	Apr 01 05:10 PM
Symbiosis II LLC	Former Board Member	Mar 24 '26	Proposed Sale	4.89	30,518	149,233		Mar 31 05:05 PM
Ugwumba Chidozie	10% Owner	Mar 31 '26	Sale	4.88	67,991	331,796	431,094	Mar 31 04:35 PM
Ugwumba Chidozie	10% Owner	Mar 27 '26	Sale	4.75	17,470	82,982	514,621	Mar 31 04:35 PM
Ugwumba Chidozie	10% Owner	Mar 30 '26	Sale	5.10	15,536	79,234	499,085	Mar 31 04:35 PM
Ugwumba Chidozie	10% Owner	Mar 25 '26	Sale	5.50	7,098	39,039	537,410	Mar 26 05:39 PM
Ugwumba Chidozie	10% Owner	Mar 24 '26	Sale	5.78	5,492	31,744	544,508	Mar 26 05:39 PM
Ugwumba Chidozie	10% Owner	Mar 26 '26	Sale	5.40	5,319	28,723	532,091	Mar 26 05:39 PM
Symbiosis II LLC	Former Board Member	Mar 24 '26	Proposed Sale	5.80	82,212	477,000		Mar 24 04:36 PM
Ugwumba Chidozie	10% Owner	Feb 03 '26	Sale	4.10	5,559	22,792	550,000	Feb 05 10:18 AM
Symbiosis II LLC	Prior board member	Jan 29 '26	Proposed Sale	4.37	60,842	265,731		Feb 03 03:36 PM
Ugwumba Chidozie	10% Owner	Jan 29 '26	Sale	4.32	15,284	66,027	565,045	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Jan 30 '26	Sale	4.13	5,686	23,483	559,359	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Feb 02 '26	Sale	4.04	3,800	15,352	555,559	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Jan 28 '26	Sale	4.91	8,717	42,800	580,329	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 26 '26	Sale	5.02	6,418	32,218	593,185	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 27 '26	Sale	5.08	4,139	21,026	589,046	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 22 '26	Sale	5.32	12,665	67,378	605,159	Jan 23 05:33 PM
Ugwumba Chidozie	10% Owner	Jan 23 '26	Sale	5.27	5,556	29,280	599,603	Jan 23 05:33 PM
Ugwumba Chidozie	10% Owner	Jan 21 '26	Sale	5.05	12,119	61,201	617,824	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 20 '26	Sale	4.80	12,432	59,674	629,943	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 16 '26	Sale	5.13	7,923	40,645	642,375	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 13 '26	Sale	4.89	26,105	127,653	682,482	Jan 16 11:16 AM
Ugwumba Chidozie	10% Owner	Jan 14 '26	Sale	5.12	19,621	100,460	662,861	Jan 16 11:16 AM
Ugwumba Chidozie	10% Owner	Jan 15 '26	Sale	5.10	12,563	64,071	650,298	Jan 16 11:16 AM
MATLIN DAVID J	Director	Jan 13 '26	Buy	6.50	33,333	216,664	477,824	Jan 13 02:48 PM
Ugwumba Chidozie	10% Owner	Jan 12 '26	Sale	5.50	32,705	179,878	708,587	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 09 '26	Sale	6.27	9,075	56,900	741,292	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 08 '26	Sale	6.09	3,195	19,458	750,367	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 05 '26	Sale	5.87	5,869	34,451	760,611	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Jan 07 '26	Sale	6.29	3,938	24,770	753,562	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Jan 06 '26	Sale	6.04	3,111	18,790	757,500	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Dec 31 '25	Sale	5.81	13,095	76,082	770,495	Jan 02 05:25 PM
Ugwumba Chidozie	10% Owner	Jan 02 '26	Sale	5.73	4,015	23,006	766,480	Jan 02 05:25 PM
Ugwumba Chidozie	10% Owner	Dec 29 '25	Sale	5.95	8,096	48,171	787,728	Dec 31 12:10 PM
Ugwumba Chidozie	10% Owner	Dec 30 '25	Sale	6.03	4,138	24,952	783,590	Dec 31 12:10 PM
Ugwumba Chidozie	10% Owner	Dec 23 '25	Sale	6.27	6,831	42,830	800,664	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 26 '25	Sale	6.32	3,350	21,172	795,824	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 24 '25	Sale	6.27	1,490	9,342	799,174	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 19 '25	Sale	6.45	5,582	36,004	387,568	Dec 23 04:37 PM
Ugwumba Chidozie	10% Owner	Dec 22 '25	Sale	6.54	4,367	28,560	383,201	Dec 23 04:37 PM
Ugwumba Chidozie	10% Owner	Dec 04 '25	Sale	6.73	72,748	489,594	521,620	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 03 '25	Sale	7.86	56,577	444,695	594,368	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 05 '25	Sale	5.94	37,235	221,176	484,385	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 08 '25	Sale	5.70	21,463	122,339	462,922	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 09 '25	Sale	5.95	15,031	89,434	447,891	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 11 '25	Sale	6.81	10,907	74,277	427,063	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 15 '25	Sale	6.49	10,580	68,664	408,880	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 10 '25	Sale	6.42	9,921	63,693	437,970	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 12 '25	Sale	6.79	7,603	51,624	419,460	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 16 '25	Sale	6.31	7,030	44,359	401,850	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 18 '25	Sale	6.33	5,816	36,815	393,150	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 17 '25	Sale	6.61	2,884	19,063	398,966	Dec 18 05:08 PM
Symbiosis II LLC	Prior Board Member	Dec 03 '25	Proposed Sale	7.46	506,384	3,775,481		Dec 05 04:14 PM
General Resonance LLC	10% Owner	Aug 21 '25	Sale	5.34	3,401	18,161	704,591	Aug 21 08:44 PM
General Resonance LLC	10% Owner	Jun 04 '25	Sale	4.04	600	2,424	707,992	Jun 04 03:23 PM
General Resonance LLC	10% Owner	Jun 02 '25	Sale	4.12	600	2,473	708,592	Jun 02 02:39 PM
General Resonance LLC	10% Owner	May 30 '25	Sale	2.80	410	1,148	709,192	May 30 02:40 PM
General Resonance LLC	10% Owner	May 29 '25	Sale	2.73	410	1,119	709,602	May 29 03:58 PM
General Resonance LLC	10% Owner	May 28 '25	Sale	2.60	420	1,090	710,012	May 28 02:05 PM
General Resonance LLC	10% Owner	May 27 '25	Sale	2.45	420	1,029	710,432	May 27 03:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLNN

Clene Inc

Upgrade your Finviz experience